Jonathan Chou

Jonathan Chou is a physician-scientist at the University of California, San Francisco (UCSF) School of Medicine, actively contributing to both clinical practice and translational research in genitourinary oncology. As an attending physician in the Genitourinary Medical Oncology Clinic and member of the Division of Hematology/Oncology, he bridges patient care with innovative investigations into cancer biology.

• MD and PhD in Biomedical Sciences, UCSF
• A.P. Giannini Postdoctoral Fellow, 2018
• Research focus on prostate and bladder cancer mechanisms

Chou's research explores cancer biology with emphasis on transcription-replication conflicts and CDK12 regulation. His lab develops novel CAR T and radioimmunotherapies for genitourinary malignancies, utilizing transcriptomic and proteomic approaches to identify therapeutic targets. Current projects investigate resistance mechanisms to antibody-drug conjugates, synthetic lethality, and immunotherapeutic targets in aggressive cancer subtypes.

His article analysis reveals expertise in prostate cancer (CDK12 biology, radioimmunotherapy), bladder cancer (TM4SF1, CA125+ cell states), and cross-cutting themes in genomic instability, translational imaging, and precision medicine. Research trends show integration of functional genomics (CRISPR screens), clinical trials (IMPACT trial), and health equity initiatives.

Scientific recognition includes:

• Young Investigator Awards (BCAN 2023, Prostate Cancer Foundation 2020)
• DoD Physician Research Award (2019)
• Multiple UCSF fellowships (2017-2018)
• Goldwater Scholar (2003)

Chou's clinical training under Eric Small, Terence Friedlander, and Chuck Ryan, combined with postdoctoral work with Felix Feng and Alan Ashworth, positions him at the intersection of clinical oncology and cutting-edge cancer research. His educational background from Stanford University and mentorship under Zena Werb further strengthens his foundation in tumor microenvironment and metastasis regulation studies.